Inflammation BiomarkersNCT06618716
Individual Differences in Acute Response to Experimental Inflammation: Microcirculatory Changes and Psychological Predictors
A study testing endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) and Placcebo in people with Inflammation Biomarkers and Inflammation, run by University Hospital, Linkoeping at 1 site in Sweden.
Trial summary
The physiological and behavioral responses to inflammatory vary greatly between individuals. The knowlegde about what causes these differences is sparse but plausible explanations are variations in sensitivity to peripheral inflammation. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Inflammation Biomarkers, Inflammation
- What is being tested?
- endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) and Placcebo
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 25 participants
- Where
- 1 siteSweden
- Study dates
- 17 Sep 2024to 11 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy
- 18-40 years-old
- Consent form signed
- Having a Swedish personal identification number (personnummer)
Who cannot join
- Non-fluent in Swedish
- Unable to read
- Unable or unwilling to provide informed consent
- BMI below 18.5 or above 25 kg/m2
- Smoking
- Excessive alcohol consumption
Show all 23Show fewer
- Pregnancy or breastfeeding
- Positive on drug screening
- Current somatic disease including skin disease affecting the measurement areas
- Current depression, anxiety, sleep disturbances or other psychiatric illnesses
- Abnormal blood analyses: abnormal clinical levels in blood cell counts, hemoglobin, sodium, potassium, chloride, calcium, phosphate, creatinine, blood urea nitrogen, uric acid, glucose, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, bilirubin, thromboplastin time and partial thromboplastin time
- High-sensitivity C-reactive protein \> 10 mg/L.
- History of cardiovascular, pneumological, immune disease
- Moderate viral or bacterial infection in the past two weeks
- Severe and/or long-term COVID-19: positive SARS-CoV-2 PCR-test or antigen-test and/or history of symptoms since February 2020 indicative of infection with SARS-CoV-2 (fever, cough, sore throat, runny or blocked nose, nausea, muscle pain, shortness of breath), which was of high intensity and/or of long duration (≥ 8 weeks).
- Recent vaccination (within previous two weeks)
- Abnormal cardiovascular measurements
- Current or previous cancer
- Any concomitant medication other than contraceptives (14 days prior to the start and throughout the study period)
- Shift work or irregular sleep-wake cycle (within 14 days of the study period)
- Needle anxiety or blood phobia
- Invisible veins in the antecubital area of the arms or very difficult blood sampling (self-reported or experienced during screening).
- Previous participation in a study involving administration of LPS
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Department of emergency medicine, Linköping University Hospital, Region Östergötland
Linköping
About this study
Official title: Individual Differences in the Acute Response to Experimentally Induced Inflammation: Microcirculatory Changes and Psychological Predictors
The physiological and behavioral responses to inflammatory vary greatly between individuals. The knowlegde about what causes these differences is sparse but plausible explanations are variations in sensitivity to peripheral inflammation. The goal of the study is to understand microcirculatory changes in skin and their possible correlation with conventional measurements of sickness and disease in humans. A better understanding of possible psychological predictors of sickness behaviour is also warranted as it may affect the results.
The general aim of the study is to assess microcirculatory changes in skin of the face, chest, hands and feet using different optical imaging techniques, and to identify psychological predictors in the acute behavioral response to experimentally induced inflammation. The participants are healthy volunteers in the age of 18-40 years of both sex/genders. The main questions to answer are:
Read more
- How do acute inflammation change microcirculation in the skin as measured by temperature, red blood cell concentration, blood flow and spectral changes correlated with fluids and other proteins.
- Can a stronger behavioral response to experimental endotoxemia be predicted by psychological factors of the individuals?
It is a blinded with-in subject, crossover design where the participants will receive placebo-injection with saline on one study day and LPS-injection the other study day in a randomized order.
Participants will on the study days
- Fill in psychometric questionnaires
- Be measured with bio-optical imaging methods at regular intervalls.
- Be monitored with regular medical parameters such as blood pressure, oxygen saturation, puls etc When the volunteers feel recovered and the medical staff are confident of the recovery the volunteers will be discharged.
Read the detailed description
Background Acute illness manifest itself not only by physiological responses such as e.g. fever, pain and nausea, but is often accompanied by psychological and behavioral changes such as sleep/wake disturbances, fatigue, loss of appetite and depression. The physiological and behavioral responses to inflammatory activation vary greatly between individuals. The knowledge about what causes these differences is sparse, but plausible explanations are variations in sensitivity to peripheral inflammation and inflammation-induced brain changes. As the skin is readily accessible, it provides an appropriate site to assess microvascular reactivity during inflammation. Moreover, recent technological advances have provided simple and non-invasive methods to assess skin microvascular function. Therefore, human cutaneous circulation could be used as a surrogate marker of systemic microvascular function in inflammation. In the present study, we use experimentally induced immunological activation in healthy humans to study microcirculatory skin changes as well as behavioral predictors of individual sensitivity to an acute inflammatory stimulus.
The model of experimental endotoxemia to induce acute inflammation The model of experimental endotoxemia is a well-accepted and frequently used model to study the neuropsychiatric effects of pro-inflammatory cytokines, both in animals and in humans. The model is based on the sterile activation of the immune system, obtained by intravenous injection of an endotoxin, lipopolysaccharide (LPS), a wall component of gram-negative bacteria such as E. coli. Injection of LPS will affect the functionality of the vascular endothelium. Positioned at the interface between circulating blood and surrounding tissue, endothelial cells, which line the inner walls of blood vessels, play a crucial role in the response to pathogens. The endothelium serves various functions essential for maintaining organ homeostasis, including vasoregulation, selective vascular permeability, and providing an anticoagulant surface. However, during infection, the normal physiological functions of the endothelium are disrupted, contributing to the organ failure characteristic of sepsis. Importantly, the response to inflammation during experimental endotoxemia differs substantially across individuals. This holds for the degree of increase in inflammatory cytokines, the neural response, as well as the behavioral changes that entail inflammation. It should be noted that the neuropsychiatric response to inflammation is not explained fully by the magnitude of the inflammatory response, indicating that other factors are involved. Recent research points toward the importance of top-down mechanisms in modifying the effect of inflammation on behavior. Such mechanisms might include pre-existent emotional status and beliefs about the intensity of which one will become sick after an infection. Identifying the predictors of a heightened behavioral response to inflammation would help identifying markers of inflammation-associated neuropsychiatric vulnerability, but this has rarely been investigated.
General aim The general aim of the study is to assess microcirculatory changes in skin of the face, chest, hands and feet using different optical imaging techniques, and to identify psychological predictors in the acute behavioral response to experimentally induced inflammation.
Primary research questions
The main research questions are:
- to assess how acute inflammation affects:
- the microcirculation in skin such as face, chest, arms, hands and feet as investigated with different non-invasive optical imaging techniques:
- Core temperature changes
- Facial temperature changes
- Changes in equivalents to red blood cell concentration and blood flow
- Spectral changes in skin possibly correlated with fluids and other proteins affected by microcirculatory changes
- to assess whether a stronger behavioral response (i.e. sickness behavior, negative mood, fatigue, anxiety, pain) to experimental endotoxemia is predicted by:
- higher interoceptive sensitivity as measured by self-report and an objective task (heartrate discrimination task);
- less cognitive resilience (i.e. self-efficacy, optimism, perseverance, coping strategies, ability to update beliefs in the fact of contradictory evidence);
- worse baseline emotional status (i.e. trait anxiety, fatigue, perceived stress);
- stronger health anxiety and disgust tendencies;
- Sociocultural factors that have been found to relate to sickness behavior, such as stoic endurance of pain and discomfort, familism, individualism, and collectivism;
- baseline biological motion pattern (walking speed, rigidity of gait, and slumped posture);
Methods Research principals The research principals are Region Östergötland, Karolinska Institutet and Stockholm University, Sweden. Data collection will be conducted at the Emergency Medicine Research Center (EMRC). Processing of data will be conducted at EMRC, Region Östergötland, Karolinska Institutet and Stockholm University.
Study design The study will be conducted at the Emergency Medicine Research Center at the University Hospital of Linköping. The study will follow a double-blind within-subject crossover placebo-controlled design. All subjects will receive an intravenous administration of LPS at a dose of up to 0.8 ng/kg body weight once, and an intravenous administration of placebo once, in a randomized order and with at least 4 weeks of wash-out period. Upon arrival, volunteers will be placed on a hospital bed in a single room and a catheter will be placed in the forearm or hand to avoid multiple needle insertion. A urine sample for pregnancy testing and drug screening will be obtained for safety reasons. The participants will then complete the baseline questionnaires, and the baseline blood sample will be drawn. After the baseline assessments, volunteers will receive the LPS or placebo injection. Vital signs (pulse, blood pressure, blood-oxygen saturation, respiratory frequency) will be continuously monitored and recorded at 30-minute intervals. Body temperature will be monitored and recorded every 30 minutes with regular tympanic thermometer, as well as continuously, using bio-optical imaging techniques. Blood samples will be taken approximately every hour to measure the inflammatory response (see "assessments - inflammatory markers from blood samples" below). Bio-optical imaging will be performed once before injection and at several occasions after the injection. Web-based questionnaires will be completed regularly to measure the sickness and emotional response will be completed by the participants just after acquisition of blood samples. Several behavioral tasks will be conducted during the study day. Volunteers will be discharged 6-10 hrs or when considered recovered by medical staff, after the injection, following a medical examination.
- Conditions
- Inflammation Biomarkers, Inflammation
- Being tested
- endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS), Placcebo
- Keywords
- Microcirculatory status, Sickness behaviour, Lipopolysaccharide, Non-invasive monitoring
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)Biological
Intravenous administration of endotoxin (0.8 ng/kg body weight)
PlacceboOther
Placebo injection of 0.9% NaCl
| Study group | Role | What they receive |
|---|---|---|
| Endotoxin | Active comparator | The USP (United States Pharmacopeia Convention) Endotoxin RS (LPS; Endotoxin Reference Standard, Escherichia coli, Pharmacopeia, Rockville, MD, US) will be ordered.and comes as a lyophilized (freeze-dried) powder, and each vial contains 10,000 USP Endotoxin Units. Each vial contains approximately 1 microgram of Endotoxin. The lyophilized LPS will be dissolved in 5mL sterile water to obtain a solution at 200 ng/mL. This solution will be aliquoted in 400μL (thus containing 80ng endotoxin) and stored at -20°C. Aliquots will be sent for microbial safety testing routine and verification of endotoxin concentration to a certified laboratory. On the study day, 2100μL of physiological saline (sterile, pyrogen-free isotonic NaCl solution) will be added to the aliquot to obtain a final concentration of 32 ng/mL. The amount of solution to inject will then be calculated according to the participant's weight [in mL = (0.8 x weight) / 32]. Receives: Biological: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) |
| Placebo | Placebo comparator | An equivolume of sterile physiological saline (NaCl 0.9%) will be used as placebo. Receives: Other: Placcebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
How does inflammation affect the behavioral response?
Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.
Measured: Baseline
How does inflammation affect the behavioral response?
Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.
Measured: during the intervention
How does inflammation affect the behavioral response?
Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.
Measured: after the intervention
Microcirculatory changes in skin measured with bio-optical instruments
- Red Blood Cell tissue fraction - %
Measured: Baseline
Microcirculatory changes in skin measured with bio-optical instruments
- Red Blood Cell tissue fraction - %
Measured: during the intervention
Microcirculatory changes in skin measured with bio-optical instruments
- Red Blood Cell tissue fraction - %
Measured: after the intervention
Microcirculatory changes in skin measured with bio-optical instruments
- Blood flow - mm/s
Measured: Baseline
Microcirculatory changes in skin measured with bio-optical instruments
Blood flow - mm/s
Measured: during the intervention
Microcirculatory changes in skin measured with bio-optical instruments
- Blood flow - mm/s
Measured: after the intervention
Changes in skin and core temperature
Measured in degrees Celsius
Measured: Baseline
Changes in skin and core temperature
Measured in degrees Celsius
Measured: during the intervention
Changes in skin and core temperature
Measured in degrees Celsius
Measured: after the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start17 Sep 2024
- Primary completion11 Mar 2025
- Study completion11 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Inflammation BiomarkersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Linkoeping
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska Institutet, Stockholm University
- Responsible party
- Principal investigator, Daniel Wilhelms, University Hospital, Linkoeping
- Investigators
- Rani Toll, PhD, Principal investigator, Department of Emergency Medicine in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06618716
- Sponsor's protocol ID
- 2023-07974-01
- Other IDs
- 2023
- Status last verified
- May 2026
- First submitted
- 12 Sep 2024
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pseudomized data on the psychometric tests and kinetic tests will be shared with other researchers.
Publications
Gustavsson H, Toll R, Fahlander S, Meyer F, Olwegard B, Hultman M, Lasselin J, Henricson J, Wilhelms D. Physiological limits of capillary refill time: a human endotoxemia study. Crit Care. 2026 Aug 31;30(1):461. doi: 10.1186/s13054-026-06247-8.
PubMed 42706575
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Individual Differences in the Acute Response to Experimentally Induced Inflammation: Microcirculatory Changes and Psychological Predictors
- ClinicalTrials.gov ID
- NCT06618716
- Acronym / sponsor ID
- 2023-07974-01
- Conditions
- Inflammation Biomarkers, Inflammation
- Keywords
- Microcirculatory status, Sickness behaviour, Lipopolysaccharide, Non-invasive monitoring
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- University Hospital, LinkoepingUniversity, hospital or other
- Collaborators
- Karolinska Institutet, Stockholm University
- Study start
- 17 Sep 2024 (actual)
- Primary completion
- 11 Mar 2025 (actual)
- Study completion
- 11 Mar 2025 (actual)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The physiological and behavioral responses to inflammatory vary greatly between individuals. The knowlegde about what causes these differences is sparse but plausible explanations are variations in sensitivity to peripheral inflammation. The goal of the study is to understand microcirculatory changes in skin and their possible correlation with conventional measurements of sickness and disease in humans. A better understanding of possible psychological predictors of sickness behaviour is also warranted as it may affect the results.
The general aim of the study is to assess microcirculatory changes in skin of the face, chest, hands and feet using different optical imaging techniques, and to identify psychological predictors in the acute behavioral response to experimentally induced inflammation. The participants are healthy volunteers in the age of 18-40 years of both sex/genders. The main questions to answer are:
- How do acute inflammation change microcirculation in the skin as measured by temperature, red blood cell concentration, blood flow and spectral changes correlated with fluids and other proteins.
- Can a stronger behavioral response to experimental endotoxemia be predicted by psychological factors of the individuals?
It is a blinded with-in subject, crossover design where the participants will receive placebo-injection with saline on one study day and LPS-injection the other study day in a randomized order.
Participants will on the study days
- Fill in psychometric questionnaires
- Be measured with bio-optical imaging methods at regular intervalls.
- Be monitored with regular medical parameters such as blood pressure, oxygen saturation, puls etc When the volunteers feel recovered and the medical staff are confident of the recovery the volunteers will be discharged.
Detailed description
Background Acute illness manifest itself not only by physiological responses such as e.g. fever, pain and nausea, but is often accompanied by psychological and behavioral changes such as sleep/wake disturbances, fatigue, loss of appetite and depression. The physiological and behavioral responses to inflammatory activation vary greatly between individuals. The knowledge about what causes these differences is sparse, but plausible explanations are variations in sensitivity to peripheral inflammation and inflammation-induced brain changes. As the skin is readily accessible, it provides an appropriate site to assess microvascular reactivity during inflammation. Moreover, recent technological advances have provided simple and non-invasive methods to assess skin microvascular function. Therefore, human cutaneous circulation could be used as a surrogate marker of systemic microvascular function in inflammation. In the present study, we use experimentally induced immunological activation in healthy humans to study microcirculatory skin changes as well as behavioral predictors of individual sensitivity to an acute inflammatory stimulus.
The model of experimental endotoxemia to induce acute inflammation The model of experimental endotoxemia is a well-accepted and frequently used model to study the neuropsychiatric effects of pro-inflammatory cytokines, both in animals and in humans. The model is based on the sterile activation of the immune system, obtained by intravenous injection of an endotoxin, lipopolysaccharide (LPS), a wall component of gram-negative bacteria such as E. coli. Injection of LPS will affect the functionality of the vascular endothelium. Positioned at the interface between circulating blood and surrounding tissue, endothelial cells, which line the inner walls of blood vessels, play a crucial role in the response to pathogens. The endothelium serves various functions essential for maintaining organ homeostasis, including vasoregulation, selective vascular permeability, and providing an anticoagulant surface. However, during infection, the normal physiological functions of the endothelium are disrupted, contributing to the organ failure characteristic of sepsis. Importantly, the response to inflammation during experimental endotoxemia differs substantially across individuals. This holds for the degree of increase in inflammatory cytokines, the neural response, as well as the behavioral changes that entail inflammation. It should be noted that the neuropsychiatric response to inflammation is not explained fully by the magnitude of the inflammatory response, indicating that other factors are involved. Recent research points toward the importance of top-down mechanisms in modifying the effect of inflammation on behavior. Such mechanisms might include pre-existent emotional status and beliefs about the intensity of which one will become sick after an infection. Identifying the predictors of a heightened behavioral response to inflammation would help identifying markers of inflammation-associated neuropsychiatric vulnerability, but this has rarely been investigated.
General aim The general aim of the study is to assess microcirculatory changes in skin of the face, chest, hands and feet using different optical imaging techniques, and to identify psychological predictors in the acute behavioral response to experimentally induced inflammation.
Primary research questions
The main research questions are:
- to assess how acute inflammation affects:
- the microcirculation in skin such as face, chest, arms, hands and feet as investigated with different non-invasive optical imaging techniques:
- Core temperature changes
- Facial temperature changes
- Changes in equivalents to red blood cell concentration and blood flow
- Spectral changes in skin possibly correlated with fluids and other proteins affected by microcirculatory changes
- to assess whether a stronger behavioral response (i.e. sickness behavior, negative mood, fatigue, anxiety, pain) to experimental endotoxemia is predicted by:
- higher interoceptive sensitivity as measured by self-report and an objective task (heartrate discrimination task);
- less cognitive resilience (i.e. self-efficacy, optimism, perseverance, coping strategies, ability to update beliefs in the fact of contradictory evidence);
- worse baseline emotional status (i.e. trait anxiety, fatigue, perceived stress);
- stronger health anxiety and disgust tendencies;
- Sociocultural factors that have been found to relate to sickness behavior, such as stoic endurance of pain and discomfort, familism, individualism, and collectivism;
- baseline biological motion pattern (walking speed, rigidity of gait, and slumped posture);
Methods Research principals The research principals are Region Östergötland, Karolinska Institutet and Stockholm University, Sweden. Data collection will be conducted at the Emergency Medicine Research Center (EMRC). Processing of data will be conducted at EMRC, Region Östergötland, Karolinska Institutet and Stockholm University.
Study design The study will be conducted at the Emergency Medicine Research Center at the University Hospital of Linköping. The study will follow a double-blind within-subject crossover placebo-controlled design. All subjects will receive an intravenous administration of LPS at a dose of up to 0.8 ng/kg body weight once, and an intravenous administration of placebo once, in a randomized order and with at least 4 weeks of wash-out period. Upon arrival, volunteers will be placed on a hospital bed in a single room and a catheter will be placed in the forearm or hand to avoid multiple needle insertion. A urine sample for pregnancy testing and drug screening will be obtained for safety reasons. The participants will then complete the baseline questionnaires, and the baseline blood sample will be drawn. After the baseline assessments, volunteers will receive the LPS or placebo injection. Vital signs (pulse, blood pressure, blood-oxygen saturation, respiratory frequency) will be continuously monitored and recorded at 30-minute intervals. Body temperature will be monitored and recorded every 30 minutes with regular tympanic thermometer, as well as continuously, using bio-optical imaging techniques. Blood samples will be taken approximately every hour to measure the inflammatory response (see "assessments - inflammatory markers from blood samples" below). Bio-optical imaging will be performed once before injection and at several occasions after the injection. Web-based questionnaires will be completed regularly to measure the sickness and emotional response will be completed by the participants just after acquisition of blood samples. Several behavioral tasks will be conducted during the study day. Volunteers will be discharged 6-10 hrs or when considered recovered by medical staff, after the injection, following a medical examination.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Endotoxin | Active comparator | Biological: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)The USP (United States Pharmacopeia Convention) Endotoxin RS (LPS; Endotoxin Reference Standard, Escherichia coli, Pharmacopeia, Rockville, MD, US) will be ordered.and comes as a lyophilized (freeze-dried) powder, and each vial contains 10,000 USP Endotoxin Units. Each vial contains approximately 1 microgram of Endotoxin. The lyophilized LPS will be dissolved in 5mL sterile water to obtain a solution at 200 ng/mL. This solution will be aliquoted in 400μL (thus containing 80ng endotoxin) and stored at -20°C. Aliquots will be sent for microbial safety testing routine and verification of endotoxin concentration to a certified laboratory. On the study day, 2100μL of physiological saline (sterile, pyrogen-free isotonic NaCl solution) will be added to the aliquot to obtain a final concentration of 32 ng/mL. The amount of solution to inject will then be calculated according to the participant's weight [in mL = (0.8 x weight) / 32]. |
| Placebo | Placebo comparator | Other: PlacceboAn equivolume of sterile physiological saline (NaCl 0.9%) will be used as placebo. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy
- 18-40 years-old
- Consent form signed
- Having a Swedish personal identification number (personnummer)
Key exclusion criteria (23 listed)
- Non-fluent in Swedish
- Unable to read
- Unable or unwilling to provide informed consent
- BMI below 18.5 or above 25 kg/m2
- Smoking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)Intravenous administration of endotoxin (0.8 ng/kg body weight) | Biological | Endotoxin |
| PlacceboPlacebo injection of 0.9% NaCl | Other | Placebo |
Primary outcome
How does inflammation affect the behavioral response?
Time frame: Baseline
Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.
How does inflammation affect the behavioral response?
Time frame: during the intervention
Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.
How does inflammation affect the behavioral response?
Time frame: after the intervention
Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.
Microcirculatory changes in skin measured with bio-optical instruments
Time frame: Baseline
- Red Blood Cell tissue fraction - %
Microcirculatory changes in skin measured with bio-optical instruments
Time frame: during the intervention
- Red Blood Cell tissue fraction - %
Microcirculatory changes in skin measured with bio-optical instruments
Time frame: after the intervention
- Red Blood Cell tissue fraction - %
Microcirculatory changes in skin measured with bio-optical instruments
Time frame: Baseline
- Blood flow - mm/s
Microcirculatory changes in skin measured with bio-optical instruments
Time frame: during the intervention
Blood flow - mm/s
Microcirculatory changes in skin measured with bio-optical instruments
Time frame: after the intervention
- Blood flow - mm/s
Changes in skin and core temperature
Time frame: Baseline
Measured in degrees Celsius
Changes in skin and core temperature
Time frame: during the intervention
Measured in degrees Celsius
Changes in skin and core temperature
Time frame: after the intervention
Measured in degrees Celsius
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Derived from this study: PubMed 42706575Gustavsson H, Toll R, Fahlander S, Meyer F, Olwegard B, Hultman M, Lasselin J, Henricson J, Wilhelms D. Physiological limits of capillary refill time: a human endotoxemia study. Crit Care. 2026 Aug 31;30(1):461. doi: 10.1186/s13054-026-06247-8.
- Individual participant dataSharing planned: Yes. Pseudomized data on the psychometric tests and kinetic tests will be shared with other researchers.
Related trials for Inflammation Biomarkers
Active, not recruitingObservational study
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
RecruitingObservational study
Predicting Functional Recovery After Coronary Chronic Total Occlusion Revascularization
Chronic Total Occlusions of Coronary Arteries, Stress Echocardiography (SE)
Active, not recruiting
Effect of a Ginger-Based Beverage on Inflammation, Oxidative Stress, and Endothelial Function
Inflammation Biomarkers, Oxidative Stress
Recruiting
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
Prediabetes, Lipid Profile
Recruiting
Walnuts for Cardiorenal Protection in Adults With Chronic Kidney Disease
CKD - Chronic Kidney Disease, Renal Function
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rani Toll, PhD principal investigator
Department of Emergency Medicine in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) and Placcebo in people with Inflammation Biomarkers and Inflammation, run by University Hospital, Linkoeping at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
How does inflammation affect the behavioral response? (time frame: Baseline). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06618716, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026; AzTrials last refreshed its copy on 30 Oct 2026.